About ULSAM, EPE - Hospital Conde de Bertiandos
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Janssen Research & Development, LLC
3
Boehringer Ingelheim
2
Pfizer
2
Janssen Pharmaceutica N.V., Belgium
1
Soraia Azevedo
1
Universidade Nova de Lisboa
1
Clinical Trials at ULSAM, EPE - Hospital Conde de Bertiandos
During the past decade, ULSAM, EPE - Hospital Conde de Bertiandos conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 4 clinical trials were completed, i.e. on
average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
2015-11-12
2018-11-28
Completed
580
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
2016-08-23
2019-07-15
Completed
154
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
2016-03-02
2018-11-14
Completed
849
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
2017-11-27
2023-01-25
Completed
444
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
2018-04-16
2020-11-05
Terminated
516
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
2019-03-22
2020-11-11
Completed
285
Efficacy of Sodium Thiosulfate in Shoulder Pain in Calcific Tendinitis of the Rotator Cuff
2020-01-01
2022-12-31
Recruiting
80
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
2021-08-30
2026-02-13
Recruiting
405
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "ULSAM, EPE - Hospital Conde de Bertiandos" #1 sponsor was "Janssen Research & Development, LLC" with 3 trials, followed by "Boehringer Ingelheim" with 2 trials
sponsored, "Pfizer" with 2 trials sponsored, "Janssen Pharmaceutica N.V., Belgium" with 1 trials sponsored and "Soraia Azevedo"
with 1 trials sponsored. Other sponsors include -4 different institutions and
companies that sponsored additional 6 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "ULSAM, EPE - Hospital Conde de Bertiandos"
#1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "CHRC-Comprehensive Health Research Centre, FCM|NMS, UNL" with 1 trials as a collaborator, "Centro Hospitalar Baixo Vouga - Hospital Infante D. Pedro" with 1 trials as a collaborator, "Centro Hospitalar Lisboa Ocidental Hospital Egas Moniz" with 1 trials as a collaborator and "Centro Hospitalar Médio Tejo - Hospital Rainha Santa Isabel - Torres Novas" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were
collaborators in the rest 13 trials.
Clinical Trials Conditions at ULSAM, EPE - Hospital Conde de Bertiandos
According to Clinical.Site data, the most researched conditions in "ULSAM, EPE - Hospital Conde de Bertiandos" are
"Arthritis, Psoriatic" (2 trials), "Arthritis, Rheumatoid" (1 trials), "Axial Spondyloarthritis" (1 trials), "Calcific Tendinitis" (1 trials) and "Lung Diseases, Interstitial" (1 trials). Many other conditions were trialed in "ULSAM, EPE - Hospital Conde de Bertiandos" in a lesser frequency.
Clinical Trials Intervention Types at ULSAM, EPE - Hospital Conde de Bertiandos
Most popular intervention types in "ULSAM, EPE - Hospital Conde de Bertiandos" are "Drug" (9 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (6 trials), "Nintedanib" (2 trials), "Guselkumab" (1 trials), "Guselkumab 100 mg" (1 trials) and "Investigational Medical Product (IMP) administered in parent study" (1 trials). Other intervention names were less common.
Clinical Trials Genders at ULSAM, EPE - Hospital Conde de Bertiandos
The vast majority of trials in "ULSAM, EPE - Hospital Conde de Bertiandos" are
10 trials for "All" genders.
Clinical Trials Status at ULSAM, EPE - Hospital Conde de Bertiandos
Currently, there are NaN active trials in "ULSAM, EPE - Hospital Conde de Bertiandos".
undefined are not yet recruiting,
4 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 5 completed trials in ULSAM, EPE - Hospital Conde de Bertiandos,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in ULSAM, EPE - Hospital Conde de Bertiandos, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 6 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".